1. Aggregation of human plasma and of human blood induced in vitro by pegfilgrastim originator formulation buffer and pegfilgrastim products;Arvinte;Eur. J. Pharmaceut. Biopharmaceut.,2023
2. NEUPOGEN® (filgrastim) injection, for subcutaneous or intravenous use. Full Prescribing Information. Amgen Inc. Thousand Oaks, CA. 03/2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5183lbl.pdf.
3. Characterization, Formulation, and Stability of Neupogen® (filgrastim), a Recombinant Human Granulocyte- Colony Stimulating FactorFormulation, Characterization, and Stability of Protein Drugs;Herman,1996
4. Biosimilar Product Information. US Food and Drug Administration: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
5. NEULASTA® (pegfilgrastim) injection for subcutaneous use. Full Prescribing Information. Amgen Inc. Thousand Oaks, CA. 06/2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125031s203lbl.pdf.